|
|
||||||||
J Thorac Cardiovasc Surg 2000;120:134-141
© 2000 The American Association for Thoracic Surgery
SURGERY FOR ACQUIRED CARDIOVASCULAR DISEASE |
From the Department of Cardiovascular Surgerya and the Department of Cardiology,b University Hospital Charité, Humboldt University Berlin, Germany.
Supported by grants of the Humboldt University Berlin.
Address for reprints: H. R. Laube, MD, PhD, Department of Cardiovascular Surgery, University Hospital Charité, Humboldt, University Berlin, Schumannstrasse 20/21, D-10117 Berlin, Germany (E-mail: horst.laube{at}charite.de ).
Objective: Autologous endothelial cell seeding was used to improve the patency of 4-mm polytetrafluoroethylene vascular prostheses.
Methods: Since 1995, 14 patients with coronary artery disease received 21 autologous endothelial cellseeded polytetrafluoroethylene vascular bypass grafts for coronary artery revascularization. The polytetrafluoroethylene grafts were seeded with the endothelial cells in a multiple step procedure, including cell culture techniques before coronary bypass operation. With the use of extracorporal circulation and cardioplegic arrest, a bypass operation was performed by means of conventional surgical techniques.
Results: After a mean postoperative follow-up of 27.7 months (range, 7.5-48 months), the graft patency rate is 90.5%. Follow-up angiograms of the aorta-coronary polytetrafluoroethylene bypass grafts showed patent bypasses in all cases except two. Angiograms of all 19 patent endothelial cellseeded polytetrafluoroethylene bypass grafts showed a smooth luminal borderline without stenotic regions. The percutaneous transluminal angioscopic evaluation showed a glossy white and smooth endoluminal graft surface without any fibrin, platelet, or erythrocyte deposits. Intravascular ultrasonographic examinations confirmed the results.
Conclusion: Patency of autologous endothelial cellseeded 4-mm polytetrafluoroethylene vascular prostheses as coronary artery bypass grafts was much better than that of unseeded polytetrafluoroethylene grafts. Further evaluations and a larger population of patients will prove whether the encouraging patency will last.
This article has been cited by other articles:
![]() |
Y. Ishii, S.-i. Sakamoto, R. T. Kronengold, R. Virmani, E. A. Rivera, S. M. Goldman, E. J. Prechtel, J. G. Hill, and R. J. Damiano Jr. A novel bioengineered small-caliber vascular graft incorporating heparin and sirolimus: Excellent 6-month patency. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1237 - 1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Kapadia, D. A. Popowich, and M. R. Kibbe Modified Prosthetic Vascular Conduits Circulation, April 8, 2008; 117(14): 1873 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lahtinen, P. Blomberg, G. Baliulis, F. Carlsson, H. Khamis, and V. Zemgulis In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 383 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gabbieri, P. M. Dohmen, C. Koch, A. Lembcke, W. Rutsch, and W. Konertz Aortocoronary Endothelial Cell-Seeded Polytetrafluoroethylene Graft: 9-Year Patency Ann. Thorac. Surg., March 1, 2007; 83(3): 1166 - 1168. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Dohmen, D. Gabbieri, A. Lembcke, and W. Konertz Endothelial Cell-Seeded Bovine Internal Mammary Artery for Complete Revascularization Ann. Thorac. Surg., March 1, 2007; 83(3): 1168 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ishii, R. T. Kronengold, R. Virmani, E. A. Rivera, S. M. Goldman, E. J. Prechtel, R. B. Schuessler, and R. J. Damiano Jr Novel Bioengineered Small Caliber Vascular Graft With Excellent One-Month Patency Ann. Thorac. Surg., February 1, 2007; 83(2): 517 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doebis, S. Schu, J. Ladhoff, A. Busch, F. Beyer, J. Reiser, R. F. Nicosia, S. Broesel, H.-D. Volk, and M. Seifert An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators Cardiovasc Res, November 1, 2006; 72(2): 331 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Pislaru, A. Harbuzariu, G. Agarwal, T. Witt AAS CVT LATG, R. Gulati, N. P. Sandhu, C. Mueske AA, M. Kalra, R. D. Simari, and G. S. Sandhu Magnetic Forces Enable Rapid Endothelialization of Synthetic Vascular Grafts Circulation, July 4, 2006; 114(1_suppl): I-314 - I-318. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Hoenig, G. R. Campbell, B. E. Rolfe, and J. H. Campbell Tissue-Engineered Blood Vessels: Alternative to Autologous Grafts? Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1128 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Folliguet, C. Rucker-Martin, C. Pavoine, E. Deroubaix, M. Henaff, J.-J. Mercadier, and S. N. Hatem Adult cardiac myocytes survive and remain excitable during long-term culture on synthetic supports J. Thorac. Cardiovasc. Surg., March 1, 2001; 121(3): 510 - 519. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |